IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don Hurst who wrote (1404)	10/1/1999 12:26:00 AM
From: Jibacoa	of 1510

Does any one knows what happened with the drug thatIMNR was working on for MS? It has been 2 years since they reported on Phase I results: "New Vaccine Helps Fight Against MS:" <<CARLSBAD, Calif., June 26, 1997 -- the publication of the results of a Phase I clinical trial, using a T cell receptor ("TCR") peptide vaccine to treat multiple sclerosis. The papers were published in the June 1997 edition of the Journal of Neuroimmunology One of the important observations of this Phase I trial is that the biological effects of the TCR peptide vaccine may translate into a clinical benefit for multiple sclerosis patients The TCR peptide vaccine was safe and well tolerated with no serious treatment-related adverse events reported. All patients had a positive immune response to the TCR peptide vaccine. The TCR peptide vaccine was developed by The Immune Response Corporation, a biopharmaceutical company based in Carlsbad, California,with technologies in the areas of HIV,autoimmune disease & gene therapy >>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next